Письмо Росздравнадзора № 16И-1437/13 от 04.12.2013 О качестве лекарственных средств Cepur
Ns
HageaHr.re
nln
neKapcTBeHHoro cpeAcTBa
flpousno4r4reJrb,
He4o6porarrecrBeHHoe
cTpaHa
I,',JTLI
Q
floxagarelr
anrcr.rSr.rrlupoBaHHoe
NCKAPCTBEHHOE CPC,ITCTBO
<<flo4wrnHocrb.
Merol
TCX)
KsaMarer, ruroQulv3ur
48
Arrfl,
Bce cepnu
npr{roToBJreHr{r pacTBopa Art
BHyrpuBeHHoro BBeAeHr,rfl 20 ur
(Qnaron 72.80 rrar) Nr5 /n
KOMrrJreKTe C pacTBoplrTeJreM lrufpvrfr xnopllAa pacTBop 0.9%
(arranyrur) 5 Mn Ns5/, KoHTypH€rt
ynaKoBKa J\bl, ua.rra KaproHHaf,
ASny6nH, KanJrlr
roMeonarr,IqecKr,re 20 nm,
49
50
Qnaxon-rarreJrbHrrrlbr reMHoro
creKJra (1). ua.mr,r KaproHHbre
Tpaynaenr C, ra6nerKrr AJUI
paccacbrBaHrlfl,
roMeo[arr,rqecKr,re 5 0 rur.,
reHarrbr nonnnporruenonue (1 ),
OAO <feaeon
Pnxrep>>, BenrpHx
ne4o6poraqecrBeHHoe
VcrauosneHr,te Sarra
neo6ecuerleHl,Ir rapaHTnlr
KaqecTBa JreKapcTBeHHoro
cpeAcTBa MeToAaMu
KOHTpOIT KaqecTBa IIo
rroKrcarenro
<<pH>>,
<<I{nernoclr>>,
<<flpospaqHocrbD
7351361.,
7351371
PuxapA Eumnep
Af,
HeAOOpOKarrecTBeHHOe
Onucanne, YnaKoBKa,
I,Iucrpyruur ro
Ascrnr
rrpuMeHerrulo
53680AA,
54959,
54960,
Eraorornrue
Xafinrrr,rnrreJrb
Xeem frvr6X,
56423
fepuaHux
He4o6poratrecrBeHHoe
Irlcrupaeruocrr
ne4o6poraqecrBeHHoe
Cpe4nrr Macca n
IIAIIKI4 KADTOHHbIC
flz rra af yuun, ra6lerrcn
51
r2J14l9r
flyuuan,
Ka[Jrr{
roMeorrarurrecKr,re 20
(50 rral,
ul
I
00 un), Sraxon-rarreJrbHlrrlbr
TeMHoro creKJra (l), nauru
KapToHHbIe
<Dapnaa
IOpou 8.B.,
noKpbrTbre
Kr4[rerrHopacrnopuu oft
o6ono.rxofi 100 ur 20 rur.,
frrarouu (l), na.mr.r KaproHHbre
52
Acrerrac
OAHOpOAHOCTb
rr0 MaCCe
Hn4epr
https://www.pharmcontrol.ru/rzn.php?letter=7578